Immunogenicity of SA 14-14-2 JE Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Healthy Infants
Interventions
BIOLOGICAL

JE Vaccine existing facility

Will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).

BIOLOGICAL

JE vaccine new plant lot 1

Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).

BIOLOGICAL

JE vaccine new plant lot 2

Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).

BIOLOGICAL

JE vaccine new plant lot 3

Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).

Trial Locations (1)

Unknown

Matlab, Chāndpur

All Listed Sponsors
lead

International Centre for Diarrhoeal Disease Research, Bangladesh

OTHER

NCT01635816 - Immunogenicity of SA 14-14-2 JE Vaccine | Biotech Hunter | Biotech Hunter